Bovine Tuberculosis (bTB) Diagnosis Market Size, Share and Growth Outlook, 2026

Bovine Tuberculosis (bTB) Diagnosis Market Snapshot: Market Size, CAGR, and Growth Outlook (2021 to 2034)

The global Bovine Tuberculosis (bTB) Diagnosis Market size is forecast to increase from $288.9 Billion in 2026 to $519.87 Billion in 2034 at a CAGR of 7.62% between 2026 and 2034.

The Bovine Tuberculosis (bTB) Diagnosis market report provides detailed analysis and outlook of Bovine Tuberculosis (bTB) Diagnosis segments including By Test Type (Traditional Skin Tests, Interferon-Gamma Assays, Serological Tests, Molecular Diagnostic Tests, Post-mortem Examination ), By Sample Type (Blood, Milk, Tissue, Fecal & Environmental Swabs), By Animal Type (Dairy Cattle, Beef Cattle, Buffalo & Bison), By End-User (Veterinary Reference Laboratories, On-farm, Government Agencies & Animal Health Departments, Academic & Research Institutes) across global and regional markets. Further, analysis and outlook across 21 countries in North America, Europe, Asia Pacific, Middle East, Africa, and South America are provided in the study.

Bovine Tuberculosis (bTB) Diagnosis Industry Overview

Growing Importance of Advanced Diagnostic Technologies in bTB Control

The bovine tuberculosis (bTB) diagnosis industry is experiencing significant advancement as animal health authorities and diagnostic developers intensify efforts to improve disease detection, surveillance, and eradication programs. Bovine tuberculosis, caused primarily by Mycobacterium bovis, remains a major challenge for cattle industries due to its economic impact, animal health implications, and regulatory significance. As governments seek faster herd clearance and more effective disease management strategies, the adoption of molecular diagnostics, blood-based testing platforms, and high-sensitivity screening methods is becoming increasingly important across veterinary healthcare systems.

Government Policies Expanding Diagnostic Testing Programs

Regulatory initiatives are playing a critical role in shaping demand for advanced bTB diagnostic solutions. The UK's Department for Environment, Food and Rural Affairs (Defra) expanded its bovine tuberculosis management framework by permitting cattle within higher-risk herds located in the Low Risk Area (LRA) to undergo testing as frequently as every six months. The updated approach incorporates advanced polymerase chain reaction (PCR) diagnostic protocols performed on post-mortem tissue samples to accelerate herd clearance processes. This policy reflects the growing emphasis on rapid molecular diagnostics capable of supporting more proactive disease monitoring and outbreak containment strategies.

Increasing Adoption of High-Sensitivity Blood Testing Methods

The industry is also benefiting from broader implementation of complementary diagnostic technologies designed to identify hidden infections that may evade conventional screening approaches. The UK government introduced government-funded voluntary Interferon-gamma (IFN-γ) blood testing services for selected cattle operations located within England's High Risk and Edge Areas. The program functions as a high-sensitivity diagnostic overlay, helping veterinarians detect concealed Mycobacterium bovis infections in herds experiencing prolonged disease breakdowns. The expansion of IFN-γ testing highlights growing recognition of multi-layered diagnostic strategies for improving disease detection accuracy and reducing transmission risks.

Molecular Diagnostics Accelerating Laboratory Testing Efficiency

Innovation among diagnostic manufacturers continues to strengthen the competitive landscape of the bovine tuberculosis diagnosis industry. IDvet completed the global rollout of its validated qualitative duplex bTB qPCR assay system, designed to target highly specific genomic sequences within the Mycobacterium tuberculosis complex (MTC) while incorporating an external internal control. The assay enables commercial laboratories to generate definitive results from lymph node samples in a fraction of the time required by traditional culture-based methods. Such advancements are accelerating laboratory workflows, enhancing diagnostic confidence, and supporting faster decision-making within national bovine tuberculosis surveillance and control programs.

Bovine Tuberculosis (bTB) Diagnosis Market Trends, Growth Drivers, Competitive Landscape, and Future Opportunities

The global Bovine Tuberculosis (bTB) Diagnosis market is witnessing increasing investments in innovation, product development, digital transformation, artificial intelligence integration, healthcare infrastructure expansion, and strategic partnerships across developed and emerging economies. Key Companies in the industry include- Thermo Fisher Scientific Inc., IDEXX Laboratories, Inc., Bio-Rad Laboratories, Inc., Zoetis Inc., Innovative Diagnostics SAS (IDvet), AsureQuality Limited, bioMérieux SA, Bionote, Inc., Neogen Corporation, Enfer Group. The Bovine Tuberculosis (bTB) Diagnosis market is expected to remain one of the most closely watched segments in the global healthcare industry, with companies focusing on niche market segments. As healthcare systems across the US, Europe, Asia-Pacific, Latin America, and Middle East & Africa continue to prioritize efficiency, access, and innovation, the Bovine Tuberculosis (bTB) Diagnosis industry outlook remains shaped by rising healthcare expenditure, demographic change, digital transformation, and product innovation.
The report provides detailed market analysis including-

• Growth Bovine Tuberculosis (bTB) Diagnosis Market size outlook across 3 scenarios- High growth, reference, and Low growth cases

• Market Trends, Drivers, Potential Opportunities, and Challenges faced by Bovine Tuberculosis (bTB) Diagnosis companies

• Porter’s Five forces analysis- Bargaining power of buyers and sellers, Threat of Substitutes and new entrants, and Intensity of competitive rivalry

• Detailed SWOT Analysis of global and regional Bovine Tuberculosis (bTB) Diagnosis markets

• Competitive analysis including business description, product analysis, and financial profiles

• Key country specific analysis detailing key factors shaping the short-term and long-term outlook

• Recent industry developments and news including mergers, acquisitions, product launches, expansions, and company announcements

Bovine Tuberculosis (bTB) Diagnosis Market Competitive Benchmarking and Company Analysis

Leading companies in Bovine Tuberculosis (bTB) Diagnosis industry include- Thermo Fisher Scientific Inc., IDEXX Laboratories, Inc., Bio-Rad Laboratories, Inc., Zoetis Inc., Innovative Diagnostics SAS (IDvet), AsureQuality Limited, bioMérieux SA, Bionote, Inc., Neogen Corporation, Enfer Group. The Bovine Tuberculosis (bTB) Diagnosis market remains moderately to highly fragmented, with competition expected to intensify as companies accelerate investments in innovation, geographic expansion, strategic partnerships, and portfolio diversification through 2034. In developed markets such as the United States, Germany, France, the United Kingdom, and Canada, competition is increasingly centered on innovation, reimbursement positioning, and value-based healthcare solutions. Meanwhile, emerging markets including China, India, Brazil, and countries across the Middle East and Africa continue to present significant opportunities for expansion due to rising healthcare expenditure, growing patient populations, and increasing access to healthcare services.

What to expect in US Bovine Tuberculosis (bTB) Diagnosis Markets in 2026 and beyond- Market Size, Share, Growth Rate, and Forecast to 2034

The US healthcare expenditure is forecast to reach $8.2 Trillion in 2034 from $5.5 Trillion in 2026 based on the National Health Expenditure Accounts (NHEA) data. With an aging population, rising chronic disease burden, and increasing migration toward minimally invasive and outpatient care, the Bovine Tuberculosis (bTB) Diagnosis market remains one of the strongest-performing segments in the country.
The US Bovine Tuberculosis (bTB) Diagnosis Companies are opting new business models, optimized pricing models, industry partnerships, and AI-enabled back end transformations to enhance efficiency and cost management. The US Bovine Tuberculosis (bTB) Diagnosis market faces successive waves of challenging trends, with strong opportunities across select segments. The CMS plan to implement Medicaid from 2027 is driving states to build eligibility verification systems throughout 2026. Looking ahead to 2034, we anticipate stronger results underpinned by opportunities exist across Bovine Tuberculosis (bTB) Diagnosis industry. On the medical device front, over 7,000 device manufacturers continue to gain from increasing demand from demand for implantable devices, surgical instruments, monitoring equipment, and diagnostic systems.

Canada- Proximity to the US and healthcare similarities to EU5 countries fuel sales of Canadian Bovine Tuberculosis (bTB) Diagnosis markets

Canada's strong Bovine Tuberculosis (bTB) Diagnosis sales performance is underpinned by an aging population and a well-developed healthcare infrastructure. Steady growth in new brand spending in rural and urban locations fuel the long-term prospects of small and medium-sized enterprises across medical, diagnostic, and therapeutic devices. The Canadian Bovine Tuberculosis (bTB) Diagnosis market presents significant opportunities for U.S. exporters of medical devices, with the U.S. being Canada’s largest trading partner for this sector. Potential advantages including specialized materials, advanced manufacturing techniques, and digital technologies support the launch of new products in the country.

Germany Bovine Tuberculosis (bTB) Diagnosis Trends and Perspectives to 2034- Financial sustainability, hospital restructuring, demographic pressures, and digitization of care delivery continue to shape the German healthcare industry.

Germany continues to remain the largest Bovine Tuberculosis (bTB) Diagnosis market in Europe, driven by over €600 Billion healthcare expenditure, €12 Billion medical device R&D expenditure, statutory health insurance system covering 90% German population, nationwide rollout of the electronic patient record (ePA), and large-volume of Bovine Tuberculosis (bTB) Diagnosis population. In particular, Research and development in Germany fuels the commercialization of cutting-edge technologies. Companies across the Germany Bovine Tuberculosis (bTB) Diagnosis industry value chain are focusing on both domestic markets and exports. The country is also driving digital adoption with the Hospital Future Act driving hospitals to upgrade their information systems by 2027. Over the forecast period, aging population, rising healthcare costs, and increasing procedural volumes drive the Bovine Tuberculosis (bTB) Diagnosis market outlook.

France Market Size, Growth Rate, and Forecast Analysis to 2034- Universal healthcare system, high public healthcare expenditure, and strong government support Bovine Tuberculosis (bTB) Diagnosis sales through 2034

France Bovine Tuberculosis (bTB) Diagnosis companies are emphasizing on opportunities for rapid, at-scale innovation to boost profitability over the long-term. The country’s National Health Insurance spending target (ONDAM) estimates 3.7% growth in the country’s healthcare expenditure. Over the forecast period, expenditure control measures, chronic disease management initiatives, workforce reforms, and efforts to improve system efficiency drive the long-term prospects.
The biggest 2026 policy frame is the PLFSS 2026. The law sets the Maladie branch spending target at €271.4 billion for 2026 and fixes the ONDAM at €117.5 billion for city care, €112.8 billion for health establishments, and €18.3 billion for elderly-care establishments and services. France’s market is also being pulled by demographics. INSEE estimates that on 1 January 2026 France had 69.1 million inhabitants, with 22% aged 65 or over. INSEE also reported that 2025 births were 645,000 and deaths were 651,000, producing a negative natural balance of about 6,000 for the first time since the end of the Second World War.

UK Bovine Tuberculosis (bTB) Diagnosis Market Size, Share, and Growth Projections to 2034- Rapid growth driven by new and existing brands across the industry value chain

Small high-need consumer segments remain key priority of Bovine Tuberculosis (bTB) Diagnosis distributors in the UK industry. Continuous launch of new products coupled with high expenditures support the market outlook. The UK Government financing remains the dominant funding source at 81.3% of total healthcare expenditure, or £280 billion in 2025. According to the ONS, total healthcare spending grew 7.7% nominally and 3.9% in real terms from 2024 to 2025. Similarly, out-of-pocket spending was £49 billion (14.1%) and voluntary health insurance was £9.5 billion (2.8%). The market is driven by rapid digital adoption with NHS England’s plan to give more than 500,000 staff access to new AI tools.

China Bovine Tuberculosis (bTB) Diagnosis Market Growth Drivers, Revenue Trends, and Forecast- Medical insurance coverage is rapidly expanding over the past few years

China Bovine Tuberculosis (bTB) Diagnosis market is undergoing a structural shift from hospital-centric care toward a more integrated system emphasizing primary care, outpatient services, and long-term care. Chinese local players are emerging as a strong pillar of Bovine Tuberculosis (bTB) Diagnosis industry, offering opportunities for both competition and partnership. Over the forecast period, new and innovative product launches remain key elements driving market outlook. China's healthcare industry is increasingly centered on expanding healthcare capacity, improving access to advanced treatments, and reducing dependence on imported technologies.
The National Healthcare Security Administration reported that by end-2024, China’s basic medical insurance covered 1.32662 billion people and the coverage rate was 95%. Regional disparities in consumer spending trends continue to become more pronounced in the Chinese Bovine Tuberculosis (bTB) Diagnosis industry. Over the forecast period, demand will keep shifting toward geriatrics, chronic disease management, rehabilitation, long-term care, and outpatient care, while pricing pressure will remain intense in drugs and consumables because reimbursement.

India Bovine Tuberculosis (bTB) Diagnosis Market Landscape: Current Size and Long-Term Growth Outlook - Increased pricing pressures in US market is encouraging domestic vendors to expand across India

Indian Bovine Tuberculosis (bTB) Diagnosis market is witnessing the rapid emergence of an ecosystem that brings together diverse companies across the industry value chain. Further, large-scale healthcare public and private investments and a steady growth in chronic conditions is driving sales of pharmaceuticals and medical devices. Further, non-retail channel is experiencing volume decrease and patients are migrating to the retail. Indian medical device firms are also combining precision engineering with lower labor costs to make world-class diagnostics, robotics, and critical care devices.

Brazil Bovine Tuberculosis (bTB) Diagnosis market remains price-driven, with products domestically manufactured and accessibility offering potential opportunities

Healthcare expenditure in Brazil exceeds 10% of GDP, with the country among the highest healthcare spenders in Latin America. ANS reported 53.2 million medical-plan beneficiaries in December 2025, while IBGE projects a steady rise in older-age cohorts, with people aged 60+ already representing about 23% of the population. The price sensitive market access is broad through the public system, private coverage adds a sizeable premium layer, and reimbursement, procurement, and hospital efficiency remain key buying drivers.

Middle East and Africa Bovine Tuberculosis (bTB) Diagnosis Industry Trends and Perspectives to 2034

According to the World Bank, the Middle East and North Africa population exceeds 500 million, while Sub-Saharan Africa's population exceeds 1.2 billion, making the broader MEA region one of the fastest-growing healthcare demand centers globally. The GCC countries including Saudi Arabia, United Arab Emirates, Qatar, and Kuwait continue to account for a disproportionately large share of regional healthcare spending. Government-led programs such as Saudi Arabia's Vision 2030 are accelerating investments in hospital infrastructure, private-sector participation, medical technology adoption, and healthcare digitalization. On the other hand, South Africa, Egypt, Nigeria, and Kenya remain key healthcare markets due to their large populations, expanding private healthcare sectors, and growing investments in healthcare delivery systems.

Bovine Tuberculosis (bTB) Diagnosis Market Segmentation

By Test Type
Traditional Skin Tests
Interferon-Gamma Assays
Serological Tests
Molecular Diagnostic Tests
Post-mortem Examination
By Sample Type
Blood
Milk
Tissue
Fecal & Environmental Swabs
By Animal Type
Dairy Cattle
Beef Cattle
Buffalo & Bison
By End-User
Veterinary Reference Laboratories
On-farm
Government Agencies & Animal Health Departments
Academic & Research Institutes

Top Companies in Bovine Tuberculosis (bTB) Diagnosis Industry

Thermo Fisher Scientific Inc.
IDEXX Laboratories, Inc.
Bio-Rad Laboratories, Inc.
Zoetis Inc.
Innovative Diagnostics SAS (IDvet)
AsureQuality Limited
bioMérieux SA
Bionote, Inc.
Neogen Corporation
Enfer Group

Countries Included

• North America- US, Canada, Mexico

• Europe- Germany, France, UK, Spain, Italy, Nordics, Others

• Asia Pacific- China, India, Japan, South Korea, Australia, Southeast Asia, Others

• Latin America- Brazil, Argentina, Others

• Middle East and Africa- Saudi Arabia, UAE, Other Middle East, South Africa, Other Africa

Latest Market Updates In Healthcare

Support this report with fresh, same-industry updates that strengthen topical depth and internal linking.

Market Update

Rise of Functional and Clinical-Grade Skincare

The rising geopolitical and tariff-related uncertainties, in particular, amidst United States’ renewed protectionist trade stance continues to driv...

June 2025